ME01916B - Novi spoj koristan u liječenju degenerativnih upalnih bolesti - Google Patents
Novi spoj koristan u liječenju degenerativnih upalnih bolestiInfo
- Publication number
- ME01916B ME01916B MEP-2014-132A MEP13214A ME01916B ME 01916 B ME01916 B ME 01916B ME P13214 A MEP13214 A ME P13214A ME 01916 B ME01916 B ME 01916B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- intended
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 21
- 238000011282 treatment Methods 0.000 title claims 11
- 230000003412 degenerative effect Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 230000002265 prevention Effects 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 201000004681 Psoriasis Diseases 0.000 claims 6
- 230000004968 inflammatory condition Effects 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 238000011321 prophylaxis Methods 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000005024 Castleman disease Diseases 0.000 claims 4
- 206010010356 Congenital anomaly Diseases 0.000 claims 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- 210000000845 cartilage Anatomy 0.000 claims 4
- 230000008414 cartilage metabolism Effects 0.000 claims 4
- 230000036244 malformation Effects 0.000 claims 4
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 239000002585 base Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Claims (20)
1. Spoj, naznačen time što je u skladu s Formulom I: ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je u obliku slobodne baze.
3. Farmaceutski pripravak, naznačen time što sadrži farmaceutski prihvatljivu podlogu i farmaceutski djelotvornu količinu spoja, ili njegove farmaceutski prihvatljive soli, u skladu s patentnim zahtjevom 1 ili 2.
4. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je namijenjen oralnoj primjeni.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je namijenjen primjeni injekcijom.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je namijenjen topikalnoj primjeni.
7. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačen time što sadrži dodatno terapijsko sredstvo.
8. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je namijenjen upotrebi kao medikament.
9. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je namijenjen upotrebi u liječenju, sprječavanju ili profilaksi upalnih stanja, autoimunih bolesti, proliferativnih bolesti, odbacivanja presadaka, bolesti koje uključuju poremećaj u metabolizmu hrskavice, prirođenih malformacija hrskavice, Castlemanove bolesti, multiplog mijeloma, psorijaze, Kaposijevog sarkoma ili mezangijskog proliferativnog glomerulonefritisa.
10. Upotreba spoja, ili njegove farmaceutski prihvatljive soli, u skladu s patentnim zahtjevom 1 ili 2, naznačena time što je spoj namijenjen pripravi medikamenta za liječenje, sprječavanje ili profilaksu upalnih stanja, autoimunih bolesti, proliferativnih bolesti, odbacivanja presadaka, bolesti koje uključuju poremećaj u metabolizmu hrskavice, prirođenih malformacija hrskavice, Castlemanove bolesti, multiplog mijeloma, psorijaze, Kaposijevog sarkoma ili mezangijskog proliferativnog glomerulonefritisa.
11. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je namijenjen liječenju, sprječavanju ili profilaksi upalnog stanja.
12. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je upalno stanje reumatoidni artritis.
13. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je namijenjen liječenju, sprječavanju ili profilaksi sistemičnog eritematoznog lupusa.
14. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je namijenjen liječenju, sprječavanju ili profilaksi psorijaze.
15. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1 ili 2, primijenjuje u kombinaciji s dodatnim terapijskim sredstvom.
16. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što je dodatno terapijsko sredstvo sredstvo za liječenje, sprječavanje ili profilaksu upalnih stanja, autoimunih bolesti, proliferativnih bolesti, odbacivanja presadaka, bolesti koje uključuju poremećaj u metabolizmu hrskavice, prirođenih malformacija hrskavice, Castlemanove bolesti, multiplog mijeloma, psorijaze, Kaposijevog sarkoma ili mezangijskog proliferativnog glomerulonefritisa.
17. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 15, naznačen time što je dodatno terapijsko sredstvo sredstvo za liječenje, sprječavanje upalnih stanja, autoimunih bolesti, proliferativnih bolesti, odbacivanja presadaka, bolesti koje uključuju poremećaj u metabolizmu hrskavice, prirođenih malformacija hrskavice, Castlemanove bolesti, multiplog mijeloma, psorijaze, Kaposijevog sarkoma ili mezangijskog proliferativnog glomerulonefritisa.
18. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 15, naznačen time što se spoj, ili njegovu farmaceutski prihvatljivu sol, suprimijenjuje s drugim terapijskim sredstvom za liječenje i/ili sprječavanje sistemičnog eritematoznog lupusa.
19. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 15, naznačen time što se spoj, ili njegovu farmaceutski prihvatljivu sol, suprimijenjuje s drugim terapijskim sredstvom za liječenje i/ili sprječavanje psorijaze.
20. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 15, naznačen time što se spoj, ili njegovu farmaceutski prihvatljivu sol, suprimijenjuje s drugim terapijskim sredstvom za liječenje i/ili sprječavanje reumatoidnog artritisa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22068509P | 2009-06-26 | 2009-06-26 | |
| US29818810P | 2010-01-25 | 2010-01-25 | |
| EP10728648.6A EP2445912B1 (en) | 2009-06-26 | 2010-06-25 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
| PCT/EP2010/059067 WO2010149771A1 (en) | 2009-06-26 | 2010-06-25 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01916B true ME01916B (me) | 2015-05-20 |
Family
ID=42340530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2014-132A ME01916B (me) | 2009-06-26 | 2010-06-25 | Novi spoj koristan u liječenju degenerativnih upalnih bolesti |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8796457B2 (me) |
| EP (2) | EP2792677B1 (me) |
| JP (1) | JP5486084B2 (me) |
| KR (1) | KR101712561B1 (me) |
| CN (1) | CN102459261B (me) |
| AR (1) | AR077221A1 (me) |
| AU (1) | AU2010264635B2 (me) |
| BR (1) | BRPI1014759A2 (me) |
| CA (1) | CA2765988C (me) |
| CL (1) | CL2011003276A1 (me) |
| CO (1) | CO6491039A2 (me) |
| CR (1) | CR20110673A (me) |
| CY (1) | CY1119711T1 (me) |
| DK (2) | DK2445912T3 (me) |
| DO (1) | DOP2011000378A (me) |
| EA (1) | EA020111B1 (me) |
| ES (2) | ES2519170T3 (me) |
| HR (2) | HRP20141057T1 (me) |
| HU (1) | HUE034205T2 (me) |
| IL (1) | IL216618A (me) |
| JO (1) | JO3030B1 (me) |
| LT (1) | LT2792677T (me) |
| MA (1) | MA33447B1 (me) |
| ME (1) | ME01916B (me) |
| MX (1) | MX2011013451A (me) |
| NZ (1) | NZ596836A (me) |
| PE (1) | PE20120494A1 (me) |
| PL (2) | PL2445912T3 (me) |
| PT (2) | PT2445912E (me) |
| RS (1) | RS53617B1 (me) |
| SG (1) | SG177359A1 (me) |
| SI (2) | SI2445912T1 (me) |
| SM (2) | SMT201700333T1 (me) |
| TW (1) | TWI469981B (me) |
| UY (1) | UY32741A (me) |
| WO (1) | WO2010149771A1 (me) |
| ZA (1) | ZA201109502B (me) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| US8637038B2 (en) | 2011-04-12 | 2014-01-28 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| SG10201914052TA (en) * | 2011-10-11 | 2020-03-30 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| MY177334A (en) * | 2012-06-22 | 2020-09-12 | Galapagos Nv | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof |
| MA38884A1 (fr) | 2013-09-05 | 2017-06-30 | Hoffmann La Roche | Composé de triazolopyridine, compositions et procédés d'utilisation associés |
| WO2015083028A1 (en) | 2013-12-05 | 2015-06-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| SG11201708198SA (en) * | 2015-04-13 | 2017-11-29 | Galapagos Nv | Methods for the treatment of cardiovascular disorders |
| US11414413B2 (en) | 2016-07-26 | 2022-08-16 | Suzhou Longbiotech Pharmaceuticals Co., Ltd. | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof |
| US11427581B2 (en) | 2018-01-31 | 2022-08-30 | Zhuhai United Laboratories Co., Ltd. | JAK inhibitor and use thereof |
| CN112955222A (zh) | 2018-08-29 | 2021-06-11 | 里珍纳龙药品有限公司 | 用于治疗患有类风湿性关节炎的个体的方法和组合物 |
| TW202521583A (zh) | 2019-01-31 | 2025-06-01 | 法商賽諾菲生物技術公司 | 用於治療幼年原發性關節炎之組成物及方法 |
| MA55760A (fr) | 2019-04-24 | 2022-03-02 | Regeneron Pharma | Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde |
| JP2022534794A (ja) | 2019-06-04 | 2022-08-03 | サノフィ・バイオテクノロジー | 関節リウマチを有する対象における疼痛を治療するための組成物および方法 |
| CN111072655B (zh) * | 2019-12-30 | 2021-12-10 | 深圳市坤健创新药物研究院 | 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用 |
| JP7766623B2 (ja) | 2020-05-19 | 2025-11-10 | サイビン アイアールエル リミテッド | 重水素化トリプタミン誘導体および使用方法 |
| US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1156037B1 (en) | 1999-01-29 | 2004-12-01 | Chugai Seiyaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
| US20040138285A1 (en) | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| US7122552B2 (en) * | 2002-05-30 | 2006-10-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of JAK and CDK2 protein kinases |
| ES2264795T3 (es) | 2003-02-14 | 2007-01-16 | Pfizer Products Inc. | Triazolo-piridinas como compuestos antiinflamatorios. |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| US20070004658A1 (en) | 2004-06-21 | 2007-01-04 | Nick Vandeghinste | Method and means for treatment of osteoarthritis |
| CA2577478A1 (en) | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds |
| US7524860B2 (en) | 2004-10-07 | 2009-04-28 | Pfizer Inc. | Antibacterial agents |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| SG174086A1 (en) * | 2006-08-30 | 2011-09-29 | Cellzome Ltd | Triazole derivatives as kinase inhibitors |
| CA2689514C (en) | 2007-06-05 | 2015-09-29 | Takeda Pharmaceutical Company Limited | Heterobicyclic compounds as kinase inhibitors |
| KR20100049073A (ko) | 2007-07-18 | 2010-05-11 | 노파르티스 아게 | 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도 |
| WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| JP2010536917A (ja) | 2007-08-31 | 2010-12-02 | メルク セローノ ソシエテ アノニム | トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法 |
| GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US20090217316A1 (en) * | 2008-02-22 | 2009-08-27 | Binita Gupta | Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service |
| AU2009259867A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| MX2011012961A (es) | 2009-06-05 | 2012-01-30 | Cephalon Inc | Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina. |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
-
2010
- 2010-05-31 JO JOP/2010/0179A patent/JO3030B1/ar active
- 2010-06-23 TW TW99120587A patent/TWI469981B/zh not_active IP Right Cessation
- 2010-06-24 AR ARP100102236A patent/AR077221A1/es active IP Right Grant
- 2010-06-25 SG SG2011096179A patent/SG177359A1/en unknown
- 2010-06-25 SM SM20170333T patent/SMT201700333T1/it unknown
- 2010-06-25 PL PL10728648T patent/PL2445912T3/pl unknown
- 2010-06-25 SI SI201030775T patent/SI2445912T1/sl unknown
- 2010-06-25 PT PT107286486T patent/PT2445912E/pt unknown
- 2010-06-25 RS RS20140614A patent/RS53617B1/sr unknown
- 2010-06-25 KR KR1020127002060A patent/KR101712561B1/ko not_active Expired - Fee Related
- 2010-06-25 MX MX2011013451A patent/MX2011013451A/es active IP Right Grant
- 2010-06-25 HR HRP20141057AT patent/HRP20141057T1/hr unknown
- 2010-06-25 LT LTEP14175887.0T patent/LT2792677T/lt unknown
- 2010-06-25 NZ NZ596836A patent/NZ596836A/xx not_active IP Right Cessation
- 2010-06-25 ES ES10728648.6T patent/ES2519170T3/es active Active
- 2010-06-25 ME MEP-2014-132A patent/ME01916B/me unknown
- 2010-06-25 ES ES14175887.0T patent/ES2634325T3/es active Active
- 2010-06-25 MA MA34555A patent/MA33447B1/fr unknown
- 2010-06-25 JP JP2012516762A patent/JP5486084B2/ja active Active
- 2010-06-25 PT PT141758870T patent/PT2792677T/pt unknown
- 2010-06-25 SI SI201031494T patent/SI2792677T1/sl unknown
- 2010-06-25 US US12/823,682 patent/US8796457B2/en active Active
- 2010-06-25 EA EA201270076A patent/EA020111B1/ru not_active IP Right Cessation
- 2010-06-25 UY UY0001032741A patent/UY32741A/es not_active Application Discontinuation
- 2010-06-25 HU HUE14175887A patent/HUE034205T2/en unknown
- 2010-06-25 EP EP14175887.0A patent/EP2792677B1/en active Active
- 2010-06-25 EP EP10728648.6A patent/EP2445912B1/en active Active
- 2010-06-25 BR BRPI1014759A patent/BRPI1014759A2/pt active Search and Examination
- 2010-06-25 DK DK10728648.6T patent/DK2445912T3/da active
- 2010-06-25 PE PE2011002144A patent/PE20120494A1/es active IP Right Grant
- 2010-06-25 CN CN201080028413.0A patent/CN102459261B/zh active Active
- 2010-06-25 DK DK14175887.0T patent/DK2792677T3/en active
- 2010-06-25 WO PCT/EP2010/059067 patent/WO2010149771A1/en not_active Ceased
- 2010-06-25 CA CA2765988A patent/CA2765988C/en not_active Expired - Fee Related
- 2010-06-25 AU AU2010264635A patent/AU2010264635B2/en not_active Ceased
- 2010-06-25 PL PL14175887T patent/PL2792677T3/pl unknown
-
2011
- 2011-11-27 IL IL216618A patent/IL216618A/en not_active IP Right Cessation
- 2011-12-06 DO DO2011000378A patent/DOP2011000378A/es unknown
- 2011-12-14 CR CR20110673A patent/CR20110673A/es unknown
- 2011-12-22 CL CL2011003276A patent/CL2011003276A1/es unknown
- 2011-12-22 ZA ZA2011/09502A patent/ZA201109502B/en unknown
-
2012
- 2012-01-16 CO CO12005375A patent/CO6491039A2/es active IP Right Grant
-
2014
- 2014-08-04 US US14/451,127 patent/US9505754B2/en active Active
- 2014-11-10 SM SM201400169T patent/SMT201400169B/xx unknown
-
2017
- 2017-07-04 HR HRP20171024TT patent/HRP20171024T1/hr unknown
- 2017-07-24 CY CY20171100784T patent/CY1119711T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01916B (me) | Novi spoj koristan u liječenju degenerativnih upalnih bolesti | |
| HRP20210343T1 (hr) | Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| HRP20200033T1 (hr) | 5-fenil-[1,2,4]triazolo[1,5-a]piridin-2-il karboksamidi kao jak inhibitori | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| CA2918938C (en) | Substituted aminopyrimidine compounds and methods of use | |
| HRP20240355T1 (hr) | 8-cijano-5-piperidino-kinolini kao tlr7/8 antagonisti i njihova upotreba u liječenju imunoloških poremećaja | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| EP2552203A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| PH12012501693A1 (en) | 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| WO2010142766A3 (en) | Pyrimidine derivatives as zap-70 inhibitors | |
| ME02576B (me) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| EP2572721A4 (en) | Pharmaceutical composition including an hif-2 inhibitor as an active ingredient for preventing or treating arthritis | |
| HK1220386A1 (zh) | Ep4受体拮抗剂在软骨疾病的治疗中的用途 | |
| HRP20120867T1 (hr) | Selurampanel | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| FR2940116B1 (fr) | Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale | |
| PL402191A1 (pl) | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję | |
| SI2858987T1 (en) | PREPARATION OF 5-PHENYL-4- (PYRIDIN-2-ILLETHYLAMINO) -CHUINAZOLIN-2-YL) -PIRIDIN-3-SULPHONAMIDE PHOSPHORAMIDIC ACID |